Changchun High-tech: Subsidiary's clinical trial application for herpes zoster vaccine approved.

Changchun High-tech Announcement: Subsidiary Baik Biological has received the "Drug Clinical Trial Approval Notice" issued by the State Drug Administration, and the clinical trial application of Baik Biological's recombinant herpes zoster vaccine has been approved. The vaccine is intended for adults aged 40 and above, and can stimulate the body to produce immunity against varicella-zoster virus, used for preventing herpes zoster. The approval of this vaccine will further enrich Baik Biological's herpes zoster vaccine product portfolio, providing more diverse vaccination options for recipients to meet market demand.